•] Shares SUTRO BIOPHARMA, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 17th, 2018 • Sutro Biopharma Inc • Biological products, (no disgnostic substances) • New York
INDEMNITY AGREEMENTIndemnity Agreement • September 17th, 2018 • Sutro Biopharma Inc • Biological products, (no disgnostic substances) • Delaware
This Indemnity Agreement, dated as of ____________________ ____, 2018 is made by and between Sutro Biopharma, Inc., a Delaware corporation (the “Company”), and _______________________________________, a director, officer or key employee of the Company or one of the Company’s subsidiaries or other service provider who satisfies the definition of Indemnifiable Person set forth below (“Indemnitee”).
AMENDED AND RESTATED EXCLUSIVE AGREEMENTExclusive Agreement • September 17th, 2018 • Sutro Biopharma Inc • Biological products, (no disgnostic substances) • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Fundamental Applied Biology, Inc. (“FAB”), a corporation having a principal place of business at 1455 Adams Drive, Bldg. 15, Suite 1015, Menlo Park, CA 94025, is effective on the 3 day of October, 2007 (“Effective Date”).
AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT by and among CELGENE CORPORATION, CELGENE ALPINE INVESTMENT COMPANY II, LLC, and SUTRO BIOPHARMA, INC. Dated as of August 2, 2017Collaboration and License Agreement • September 17th, 2018 • Sutro Biopharma Inc • Biological products, (no disgnostic substances) • New York
This AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into on the 2nd day of August, 2017 (the “Amendment Effective Date”) by and among Celgene Corporation, a Delaware corporation (“Celgene Corp.”), with respect to all rights and obligations under this Agreement in the United States (subject to Section 14.14), Celgene Alpine Investment Company II, LLC, a Delaware limited liability company (“Celgene Alpine”), with respect to all rights and obligations under this Agreement outside of the United States (subject to Section 14.14) (Celgene Corp. and Celgene Alpine together, “CELGENE”) and Sutro Biopharma, Inc., a Delaware corporation (“SUTRO”). CELGENE and SUTRO are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
EXCLUSIVE PATENT LICENSE AND RESEARCH COLLABORATION AGREEMENT by and between SUTRO BIOPHARMA, INC. and MERCK SHARP & DOHME CORP.Exclusive Patent License and Research Collaboration Agreement • September 17th, 2018 • Sutro Biopharma Inc • Biological products, (no disgnostic substances) • New York
This Agreement (“Agreement”) is effective as of July 23rd, 2018, (the “Effective Date”) and is entered into by and between SUTRO BIOPHARMA, INC., a corporation organized and existing under the laws of Delaware (“Sutro”) and MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey (“Merck”).
